BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, BioAge Labs presently has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

Shares of NASDAQ:BIOA opened at $11.83 on Friday. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $11.96. The company has a market cap of $424.11 million, a PE ratio of -7.78 and a beta of 1.72. The stock’s 50-day moving average price is $7.47.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Buying and Selling at BioAge Labs

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of BioAge Labs stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after acquiring an additional 93,694 shares in the last quarter. Geode Capital Management LLC raised its position in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Millennium Management LLC boosted its stake in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after purchasing an additional 270,479 shares in the last quarter. Marshall Wace LLP boosted its stake in shares of BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares in the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in shares of BioAge Labs by 202.2% during the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock worth $624,000 after purchasing an additional 101,085 shares during the last quarter.

About BioAge Labs

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.